Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Cristina Guarnera
Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Related publications
Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Natalizumab: A New Treatment for Relapsing Remitting Multiple Sclerosis
Therapeutics and Clinical Risk Management
Chemical Health
Pharmacology
Safety
Medicine
Toxicology
Safety Research
Pharmaceutics
Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis
Neurotherapeutics
Neurology
Pharmacology
Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England
Journal of Medical Economics
Health Policy
PND14 Budgetary Impact of the Treatment of Relapsing-Remitting Multiple Sclerosis in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis
Archives of Neurology
Alemtuzumab in the Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis: An Update on the Clinical Trial Evidence and Data From the Real World
Therapeutic Advances in Neurological Disorders
Neurology
Pharmacology
Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting
Journal of Neurology & Neurophysiology
Intravenous Immunoglobulin G for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis
European Journal of Neurology
Neurology
